TP53 and prostate carcinoma: Recurrent alterations in prostate cancer metastases included FOXA1 mutation (11/36 samples, 6/20 patients), TP53 mutation (11 samples, 7 patients), RB1 mutation (9 samples, 3 patients), homozygous or heterozygous deletion of PTEN (21 samples, 11 patients), copy number gain of MYC (9 samples, 6 patients) and FOXA1 (8 samples, 2 patients), breakpoint disruption resulting in heterozygous deletion of TP53 (7 samples, 5 patients) and breakpoint disruption resulting in partial copy gain of CSMD3 (8 samples, 4 patients).